RSVpreF cuts RSV-related respiratory hospitalizations ~70% versus no vaccine in expanded ESC 2026 follow-up.
Why the trial?
RSV infection in older adults triggers both respiratory and cardiovascular hospitalisations, but whether RSV vaccination prevents these cardiorespiratory events had not been demonstrated in a randomised trial powered for clinical outcomes.
Does bivalent RSVpreF vaccine prevent RSV-related respiratory hospitalization in adults?
Population
Adults >=60 (2025 primary cohort) plus a broader adult cohort; N not reported
Comparison
Bivalent RSVpreF vaccine vs no vaccine
Design
Pragmatic randomized trial (ESC 2026: expanded follow-up of the 2025 NEJM primary)
Key result
Expanded DAN-RSV follow-up at ESC 2026: RSVpreF cut RSV-related respiratory hospitalizations versus no vaccine (0.16 vs 0.55 per 1000 person-years; ~70% vaccine effectiveness).
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts view DAN-RSV's ~70% vaccine effectiveness against RSV-related respiratory hospitalization as compelling real-world evidence, though some flag very low event rates and an open question on all-cause mortality.
Most commentators see DAN-RSV as strong pragmatic evidence that RSV vaccination protects older adults from hospitalization, with particular relevance for those with cardiovascular disease. One voice raises concern that absolute event rates were very low and that a numerical imbalance in all-cause deaths deserves scrutiny. The live questions are whether RSV vaccination will be formally folded into cardiovascular prevention guidelines and what the optimal revaccination interval should be.
Agreement
Multiple clinicians and trial investigators agree that RSV vaccination can reduce cardiorespiratory hospitalizations in older adults and deserves broader consideration as a preventive strategy alongside influenza and COVID-19 vaccines.
4 clinicians say this directly
Main debate
Striking protection vs. low absolute events and a mortality signal
Strong real-world protection2
A 70% reduction in RSV hospitalization in a massive pragmatic trial is a clear and meaningful result.vs
Low event rates, mortality question1
Very few RSV events occurred in either group, and all-cause deaths were numerically higher in the vaccine arm.Not placed5 reporting, watching, or context only
3 takes classified by contention axis so far — the map appears as more land.
Still unclear
The optimal revaccination interval remains unknown, as flagged by one commentator. Whether the numerical imbalance in all-cause deaths is a chance finding or a real signal needs longer follow-up. It is also unclear whether guideline bodies will formally recommend RSV vaccination as part of cardiovascular prevention.
Key expert perspectives
Very low event rates and a numerical mortality imbalance deserve scrutiny
Points out that RSV events were rare in both arms (0.11 vs 0.37 per 1000 person-years in the subset he cites) and highlights that all-cause deaths were numerically higher in the vaccine group (146 vs 120, RR 1.22, 0.96-1.55). He frames this as a finding that warrants attention despite high relative vaccine efficacy.
Distilled from their postX post
A striking effect in a huge pragmatic trial that links RSV vaccination to cardiovascular prevention
Frames RSV vaccination as a potential cardiovascular preventive strategy, noting that RSV can precipitate heart failure decompensation and CV events. Calls the 70.3% vaccine effectiveness against RSV-related respiratory hospitalization a striking result.
RSV vaccination is an underutilised, cheap way to protect cardiovascular patients
Argues that DAN-RSV shows clear data that patients with cardiovascular disease are at risk from RSV infection and that vaccination is an underutilised and affordable protective strategy.
Distilled from their postX post
Overview
Supports RSVpreF vaccination in older adults with CVD; extends efficacy data to cardiorespiratory hospitalization prevention.
Key Points
- To determine the clinical effectiveness of the bivalent RSV prefusion F vaccine against respiratory-related hospitalizations in older adults.
- Pragmatic randomized trial (DAN-RSV) evaluating bivalent RSVpreF versus no vaccine in adults aged 60 years and older.
- Extended follow-up evaluating outcomes in a broader adult cohort.
- Expanded ESC 2026 follow-up: ~70% vaccine effectiveness against RSV-related respiratory hospitalization (0.16 vs 0.55 per 1000 person-years).
- Expanded cohort follow-up demonstrated an RSV-related respiratory hospitalization rate of 0.16 vs 0.55 per 1000 person-years, reflecting approximately 70% vaccine effectiveness.
Evidence details
What drove the result?
| Outcome | RSVpreF | No vaccine |
|---|---|---|
| RSV respiratory hospitalization, adults >=60 (2025 primary) | 0.11 | 0.66 |
| Per 1000 participant-years; 83.3% vaccine effectiveness (2025 NEJM primary) | ||
| RSV respiratory hospitalization, expanded cohort | 0.16 | 0.55 |
| Per 1000 person-years; ~70% effectiveness in ESC 2026 expanded follow-up incl. broader adult cohort | ||
Limitations & tradeoffs
Design limitations
the ESC 2026 readout is an expanded follow-up without a new results paper; the 2025 NEJM publication remains the primary source.
Statistical certainty
cohort sizes, confidence intervals, and follow-up duration are not reported in the record.
Structured PICO
Does bivalent RSVpreF vaccine prevent RSV-related respiratory hospitalization in adults?
P
Population
Adults ≥60 years of age evaluated for the prevention of RSV-related respiratory hospitalization.
I
Intervention
Bivalent RSVpreF vaccine
C
Comparator
No vaccine
O
Outcome
RSV-related respiratory hospitalizationhard clinical
Main Result
Effect estimate: 83.3% vaccine effectiveness
Absolute Event Rate: 0.11% vs 0.66%
The bivalent RSVpreF vaccine significantly reduces RSV-related respiratory hospitalizations in older adults and broader adult cohorts.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Lassen et al. (2026) conducted an RCT in RSV. Bivalent RSVpreF vaccine vs. No vaccine was evaluated on RSV-related respiratory hospitalization (83.3% vaccine effectiveness). Expanded DAN-RSV follow-up at ESC 2026: RSVpreF cut RSV-related respiratory hospitalizations versus no vaccine (0.16 vs 0.55 per 1000 person-years; ~70% vaccine effectiveness).